A Phase 1 Open-Label Non-Randomized Dose Escalating Safety Tolerability and Pharmacokinetic Study of TAS-114 in Combination with Capecitabine in Patients with Advanced Solid Tumors
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this exploratory study is to investigate the safety and determine the maximum tolerated dose (MTD) of TAS-114 in combination with capecitabine in patients with advanced solid tumors for which the patients have no available therapy likely to convey clinical benefit.
Description
The purpose of this exploratory study is to investigate the safety and determine the maximum tolerated dose (MTD) of TAS-114 in combination with capecitabine in patients with advanced solid tumors for which the patients have no available therapy likely to convey clinical benefit.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Neoplasms
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
25 Apr 2024.
Study ID: 1208009441 (TPU-TAS-114-1
